BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 5, 2012
View Archived Issues
Mitsubishi Tanabe Pharma offers overview of second quarter 2012
Read More
Encouraging phase III results presented for Biocon's insulin biosimilar
Read More
Cubist Pharmaceuticals begins phase III program for CB-5945
Read More
European Commission denies marketing authorization for taliglucerase alfa
Read More
Phase I results reported for ICT-107 in glioblastoma multiforme
Read More
British and French group presents novel vaccines for AIDS
Read More
Qilu Pharmaceutical discloses novel EGFR inhibitors
Read More
Shanghai Allist Pharmaceutical patents new PI3K inhibitors
Read More
Novel tyrosine-protein kinase inhibitors prepared at Pharmascience
Read More
Phase II study of GS-7340 meets 24-week primary objective
Read More
Lundbeck prepares new antibodies for Alzheimer's disease
Read More
New CSF-1 receptor inhibitors divulged by Pharmascience
Read More
Sanofi presents pipeline highlights of third quarter 2012
Read More
Degarelix evaluated in women undergoing in vitro fertilization
Read More
Immune Response BioPharma publishes full results from phase III study of HIV vaccine
Read More
Vertex enters agreements for VX-135 combination studies
Read More
Lisdexamfetamine mesilate proves beneficial in cognitively impaired MS patients
Read More
FDA requests additional information in CRL for lixivaptan NDA
Read More
AlphaCore obtains EMA orphan drug designation for ACP-501
Read More
Aerie reports topline data from phase IIa studies of its ROCK inhibitors
Read More
Glybera gene therapy approved by the European Commission
Read More
Hutchison MediPharma begins phase I study of novel EGFR inhibitor
Read More
BAX B-01 shows promise in model of proliferative nephritis
Read More
Phase III trial of Adcetris in advanced Hodgkin's lymphoma begins
Read More
Keryx Biopharmaceuticals commences phase II study of Zerenex
Read More